NTC
XLRN

NF Trinity Capital’s Acceleron Pharma XLRN Stock Holding History

NF Trinity Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,369
Closed -$626K – 48
2018
Q4 		$626K Hold
14,369
– – 0.1% 47
2018
Q3 		$822K Hold
14,369
– – 0.11% 53
2018
Q2 		$697K Hold
14,369
– – 0.1% 57
2018
Q1 		$562K Buy
+14,369
New +$611K 0.08% 58

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NF Trinity Capital's XLRN Position: Q1 2019 in Review

NF Trinity Capital sold out of Acceleron Pharma (XLRN) in Q1 2019, closing a stake of 14,369 shares — an estimated $626K sold.

NF Trinity Capital first reported a position in XLRN in Q1 2018 and held it in 4 quarters. The position peaked at $822K in Q3 2018. 171 funds tracked by Wall St. Rank hold XLRN as of Q1 2019.

  • NF Trinity Capital reported no remaining Acceleron Pharma position as of Q1 2019 after selling out during the quarter.
  • NF Trinity Capital sold 14,369 Acceleron Pharma shares in Q1 2019, an estimated $626K.
  • NF Trinity Capital first reported a position in Acceleron Pharma in Q1 2018 and held it in 4 quarters.
  • NF Trinity Capital's Acceleron Pharma position peaked at $822K in Q3 2018.
  • 171 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.